(Q37683539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Alain Li-Wan-Po

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Peter Farndon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Michael Griffiths

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

29 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

369-374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

17 January 2020

cites work

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

1 reference

12 December 2020

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

1 reference

12 December 2020

Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.

1 reference

12 December 2020

Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib

1 reference

12 December 2020

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

1 reference

12 December 2020

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

1 reference

12 December 2020

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?

1 reference

12 December 2020

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

12 December 2020

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

1 reference

12 December 2020

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia

1 reference

12 December 2020

Imatinib resistance in CML.

1 reference

12 December 2020

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

12 December 2020

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).

1 reference

12 December 2020

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

12 December 2020

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

1 reference

12 December 2020

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

1 reference

12 December 2020

The drug transporter-metabolism alliance: uncovering and defining the interplay

1 reference

12 December 2020

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

12 December 2020

PXR, CAR and drug metabolism

1 reference

12 December 2020

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

12 December 2020

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

12 December 2020

Cytochrome P450 3A and their regulation

1 reference

12 December 2020

Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence

1 reference

12 December 2020

When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example

1 reference

12 December 2020

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

12 December 2020

Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

1 reference

12 December 2020

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

1 reference

12 December 2020

Treatment selection after imatinib resistance in chronic myeloid leukemia

1 reference

12 December 2020

Clinical pharmacokinetics of imatinib

1 reference

12 December 2020

MicroRNA reexpression as differentiation therapy in cancer

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

1 reference

12 December 2020

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

A molecular star in the wars against cancer

1 reference

12 December 2020

10.1007/S00228-009-0779-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20111860%20AND%20SRC:MED&resulttype=core&format=json

release_kndhjvyownhg7nd6qutc3djd44

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kndhjvyownhg7nd6qutc3djd44

24 November 2022

mapped directly with Wikidata item

1 reference